USP22 and cancer: Moreover, synthetic lethal strategies have the unique benefit of enabling targeting of loss-of-function alterations, which would be relevant for cancer types frequently exhibiting reduced expression of E3 ubiquitin ligases (e.g., RNF20 or RNF40) or DUBs (e.g., BAP1 or USP22).